TWI905228B - 嘧啶化合物之結晶 - Google Patents

嘧啶化合物之結晶

Info

Publication number
TWI905228B
TWI905228B TW110125852A TW110125852A TWI905228B TW I905228 B TWI905228 B TW I905228B TW 110125852 A TW110125852 A TW 110125852A TW 110125852 A TW110125852 A TW 110125852A TW I905228 B TWI905228 B TW I905228B
Authority
TW
Taiwan
Prior art keywords
crystals
compound
leu
pro
gly
Prior art date
Application number
TW110125852A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216717A (zh
Inventor
中村浩之
山中博義
浅井隆宏
Original Assignee
日商大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202216717A publication Critical patent/TW202216717A/zh
Application granted granted Critical
Publication of TWI905228B publication Critical patent/TWI905228B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
TW110125852A 2020-07-15 2021-07-14 嘧啶化合物之結晶 TWI905228B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-121520 2020-07-15
JP2020121520 2020-07-15

Publications (2)

Publication Number Publication Date
TW202216717A TW202216717A (zh) 2022-05-01
TWI905228B true TWI905228B (zh) 2025-11-21

Family

ID=79554693

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110125852A TWI905228B (zh) 2020-07-15 2021-07-14 嘧啶化合物之結晶

Country Status (12)

Country Link
US (1) US12492208B2 (https=)
EP (1) EP4183788A4 (https=)
JP (1) JP7391226B2 (https=)
KR (1) KR102914926B1 (https=)
CN (1) CN116249534B (https=)
AU (1) AU2021307245B2 (https=)
BR (1) BR112023000765A2 (https=)
MX (1) MX2023000692A (https=)
MY (1) MY207540A (https=)
PH (1) PH12023550116A1 (https=)
TW (1) TWI905228B (https=)
WO (1) WO2022014638A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351737A4 (en) * 2021-05-24 2025-05-14 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017038838A1 (ja) * 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
TW201840568A (zh) * 2017-02-28 2018-11-16 日商大鵬藥品工業股份有限公司 使用吡唑并[3,4-d]嘧啶化合物之抗腫瘤效果增強劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
KR101852738B1 (ko) * 2015-01-30 2018-04-27 다이호야쿠힌고교 가부시키가이샤 축합 피리미딘 화합물의 신규한 염 및 그 결정
JP6537601B2 (ja) * 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
WO2020004546A1 (ja) 2018-06-28 2020-01-02 日本電気株式会社 遠隔制御装置、遠隔制御方法及びプログラム
MA53509A (fr) 2018-08-29 2021-07-07 Taiho Pharmaceutical Co Ltd Agent thérapeutique contenant un composé pyrazolo[3,4-d]pyrimidine comme ingrédient actif
PL3909584T3 (pl) * 2019-01-11 2024-03-25 Taiho Pharmaceutical Co., Ltd. Związek pirymidynowy lub jego sól
JP7164455B2 (ja) 2019-01-31 2022-11-01 理想科学工業株式会社 容器
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
MX2023000693A (es) 2020-07-15 2023-02-13 Taiho Pharmaceutical Co Ltd Inhibidor de egfr.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017038838A1 (ja) * 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
TW201840568A (zh) * 2017-02-28 2018-11-16 日商大鵬藥品工業股份有限公司 使用吡唑并[3,4-d]嘧啶化合物之抗腫瘤效果增強劑

Also Published As

Publication number Publication date
JP7391226B2 (ja) 2023-12-04
JPWO2022014638A1 (https=) 2022-01-20
US20230331730A1 (en) 2023-10-19
KR20230034341A (ko) 2023-03-09
MX2023000692A (es) 2023-02-13
CA3189457A1 (en) 2022-01-20
US12492208B2 (en) 2025-12-09
PH12023550116A1 (en) 2024-06-24
WO2022014638A1 (ja) 2022-01-20
BR112023000765A2 (pt) 2023-02-07
CN116249534A (zh) 2023-06-09
EP4183788A1 (en) 2023-05-24
MY207540A (en) 2025-03-04
TW202216717A (zh) 2022-05-01
CN116249534B (zh) 2025-03-25
EP4183788A4 (en) 2024-07-17
KR102914926B1 (ko) 2026-01-19
AU2021307245B2 (en) 2024-02-29
AU2021307245A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
KR102873219B1 (ko) Egfr 저해제
KR102640463B1 (ko) 피리미딘 화합물 또는 그 염
TWI568730B (zh) 刻痕（ｎｏｔｃｈ）路徑信號抑制劑化合物
TW201922257A (zh) 巨環trk激酶抑制劑之調配物
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
EA018372B1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
JP7054528B2 (ja) プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用
TWI905228B (zh) 嘧啶化合物之結晶
TW202216151A (zh) 含有使用於腫瘤之治療之嘧啶化合物之組合
RU2828232C1 (ru) Кристалл соединения пиримидина
CA3189457C (en) Crystal of pyrimidine compound
HK40087564B (zh) 嘧啶化合物的结晶
HK40087564A (zh) 嘧啶化合物的结晶
RU2787992C1 (ru) Пиримидиновое соединение или его соль
HK40056369A (en) Pyrimidine compound or salt thereof
HK40056369B (zh) 嘧啶化合物或其盐
WO2024140754A1 (zh) 一种萘酰胺类化合物、其制备方法及其应用